Effects of All-trans retinoic acid (ATRA) on human myeloma cells

Leukemia and Lymphoma

Volumn 44, Issue 10, 2003, Pages 1651-1656

  Otsuki, Takemi ^a   Sakaguchi, Haruko ^a   Hatayama, Tamayo ^a   Wu, Ping ^a   Takata, Akiko ^a   Hyodoh, Fuminori ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

ATRA; Expression; Interleukin 10; Interleukin 6; Myeloma; p21 Cip1

Indexed keywords

ALPHA INTERFERON; ARSENIC TRIOXIDE; DEXAMETHASONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; PROTEIN P21; RETINOIC ACID; RETINOL; THALIDOMIDE; THALIDOMIDE DERIVATIVE;

AEROBIC METABOLISM; ANTINEOPLASTIC ACTIVITY; AUTOCRINE EFFECT; CANCER INHIBITION; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; DOWN REGULATION; DRUG MECHANISM; HUMAN; MYELOMA; MYELOMA CELL; PARACRINE SIGNALING; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; HUMANS; INTERLEUKIN-6; MULTIPLE MYELOMA; RECEPTORS, INTERLEUKIN-6; TRETINOIN;

EID: 0141838899     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819031000099652     Document Type: Review

References (45)

1. Hofmann, S.L. (1992) "Retinoids-"differentiation agents" for cancer treatment and prevention", Am. J. Med. Sci. 304, 202-213.
2. Simoni, D. and Tolomeo, M. (2001) "Retinoids, apoptosis and cancer", Curr Pharm. Des. 7, 1823-1837.
3. Reynolds, C.P. and Lemons, R.S. (2001) "Retinoid therapy of childhood cancer", Hematol. Oncol. Clin. N. Am. 15, 867-910.
4. Ozpolat, B. and Lopez-Berestein, G. (2002) "Liposomal-all-transretinoic acid in treatment of acute promyelocytic leukemia", Leuk. Lymphoma 43, 933-941.
5. Hozumi, M. (1998) "Differentiation therapy of leukemia: achievements, limitations and future prospects", Int. J. Hematol. 68, 107-129.
6. Slack, J.L. and Gallagher, R.E. (1999) "The molecular biology of acute promyelocytic leukemia", Cancer Treat. Res. 99, 75-124.
7. Miyauchi, J. (1999) "All-trans retinoic acid and hematopoietic growth factors regulating the growth and differentiation of blast progenitors in acute promyelocytic leukemia", Leuk. Lymphoma 33, 267-280.
8. Bruserud, O. and Gjertsen, B.T. (2000) "New strategies for the treatment of acute myelogenous leukemia differentiation induction - present use and future possibilities", Stem Cells 18, 157-165.
9. Zhang, J.W., Wang, J.Y., Chen, S.J. and Chen, Z. (2000) "Mechanisms of all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells", J. Biosci. 25, 275-284.
10. Degos, L. and Wang, Z.Y. (2001) "All trans retinoic acid in acute promyelocytic leukemia", Oncogene 20, 7140-7145.
11. Tallman, M.S., Nabhan, C., Feusner, J.H. and Rowe, J.M. (2002) "Acute promyelocytic leukemia: evolving therapeutic strategies", Blood 99, 759-767.
12. Zelent, A., Guidez, F., Melnick, A., Waxman, S. and Licht, J.D. (2001) "Translocations of the RARalpha gene in acute promyelocytic leukemia", Oncogene 20, 7186-7203.
13. Benoit, G., Roussel, M., Pendino, F., Segal-Bendirdjian, E. and Lanotte, M. (2001) "Orchestration of multiple arrays of signal cross-talk and combinatorial interactions for maturation and cell death: another vision of t(15;17) preleukemic blast and APL-cell maturation", Oncogene 20, 7161-7177.
14. Cassinat, B. and Chomienne, C. (2001) "Biological features of primary APL blasts: their relevance to the understanding of granulopoiesis, leukemogenesis and patient management", Oncogene 20, 7154-7160.
15. Sidell, N., Taga, T., Hirano, T., Kishimoto, T. and Saxon, A. (1991) "Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors", J. Immunol. 146, 3809-3814.
16. Ogata, A., Nishimoto, N., Shima, Y., Yoshizaki, K. and Kishimoto, T. (1994) "Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction", Blood 84, 3040-3046.
17. Joseph, B., Lefebvre, O., Mereau-Richard, C., Danze, P.M., Belin-Plancot, M.T. and Formstecher, P. (1998) "Evidence for the involvement of both retinoic acid receptor- and retinoic X receptor-dependent signaling pathways in the induction of tissue transglutaminase and apoptosis in the human myeloma cell line RPMI 8226", Blood 91, 2423-2432.
18. Okamura, T., Masuda, M., Arai, Y., Ishida, C., Shudou, K. and Mizoguchi, H. "All-trans retinoic acid modulates Fas antigen expression and affects cell proliferation and apoptosis in combination with anti-Fas monoclonal antibody in the human myeloma cell line", U266B1. Exp. Hematol. 26, 501-506.
19. Labaume, S., Chopin, M., Pla, M. and Brouet, J.C. (1998) "Differential in vitro and in vivo effects of all-trans retinoic acid on the growth of human myeloma cells", Leuk. Lymphoma 30, 361-366.
20. Taetle, R., Dos Santos, B., Akamatsu, K., Koishihara, Y. and Ohsugi, Y. (1996) "Effects of all-trans retinoic acid and antireceptor antibodies on growth and programmed cell death of human myeloma cells", Clin. Cancer Res. 2, 253-259.
21. Tosi, P., Pellacani, A., Visani, G., Ottaviani, E., Ronconi, S., Zamagni, E., Benni, M., Cavo, M. and Tura, S. (1999) "In vitro treatment with retinoids decreases bcl-2 protein expression and enhances dexamethasone-induced cytotoxicity and apoptosis in multiple myeloma cells", Eur. J. Haematol. 62, 143-148.
22. Chen, Y.H., Lavelle, D., DeSimone, J., Uddin, S., Platanias, L.C. and Hankewych, M. (1999) "Growth inhibition of a human myeloma cell line by all-trans retinoic acid is not mediated through downregulation of interleukin-6 receptors but through upregulation of p21 (WAF1)", Blood 94, 251-259.
23. Swaminathan, N., Lopez-Berestein, G. and Rudikoff, S. (1999) "Assessment of all-trans retinoic acid (ATRA) efficacy as a single agent in primary lymphoid neoplasia", Med. Oncol. 16, 119-128.
24. WAF1 and dephosphorylation of the retinoblastoma protein", Leuk. Lymphoma 35, 261-268.
25. Honemann, D., Chatterjee, M., Savino, R., Bommert, K., Burger,R., Gramatzki, M., Dorken, B. and Bargou, R.C. (2001) "The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells", Int. J. Cancer 93, 674-680.
26. Jia, P., Chen, G., Huang, X., Cai, X., Yang, J., Wang, L., Zhou, Y., Shen, Y., Zhou, L., Yu, Y., Chen, S., Zhang, X. and Wang, Z., "Arsenic trioxide induces multiple myeloma cell apoptosis via disruption of mitochondrial transmembrane potentials and activation of caspase-3." Chin. Med. J. 114, 19-24.
27. Otsuki, T., Yata, K., Sakaguchi, H., Kurebayashi, J., Matsuo, Y. Uno, M., Fujii, T., Eda, S., Isozaki, Y., Yawata, Y., Yamada, O., Wada, H., Sugihara, T. and Ueki, A., "Interleukin 10 abolishes the growth inhibitory effects of all-trans retinoic acid on human myeloma cells." Br. J. Haematol. 116, 787-795.
28. Niesvizky, R., Siegel, D.S., Busquets, X., Nichols, G., Muindi, J., Warrell, R.P., Jr and Michaeli, J. (1995) "Hypercalcaemia and increased serum interleukin-6 levels induced by all-trans retinoic acid in patients with multiple myeloma", Br. J. Haematol. 89, 217-218.
29. Musto, P., Sajeva, M.R., Sanpaolo, G., D'Arena, G., Scalzulli, P.R. and Carotenuto, M. (1997) "All-trans retinoic acid in combination with alpha-interferon and dexamethasone for advanced multiple myeloma", Haematologica 82, 354-356.
30. Gado, K., Domjan, G., Hegyesi, H. and Falus, A. (2000) "Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma", Cell Biol. Int. 24, 195-209.
31. Anderson, K.C. and Lust, J.A. (1999) "Role of cytokines in multiple myeloma", Semin. Hematol. 36(1S3), 14-20.
32. Gartel, A.L. and Tyner, A.L. (2002) "The role of the cyclin-dependent kinase inhibitor p21 in apoptosis", Mol. Cancer Ther. 1, 639-649.
33. Boulaire, J., Fotedar, A. and Fotedar, R. (2000) "The functions of the cdk-cyclin kinase inhibitor p21WAF1* Pathol. Biol. (Paris) 48, 190-202.
34. Colman, M.S., Afshari, C.A. and Barrett, J.C. (2000) "Regulation of p53 stability and activity in response to genotoxic stress", Mutat. Res. 462, 179-188.
35. Otsuki, T., Yata, K., Sakaguchi, H., Uno, M., Fujii, T., Wada, H., Sugihara, T. and Ueki, A. (2002) "IL-10 in myeloma cells", Leuk. Lymphoma 43, 969-974.
36. Otsuki, T., Yamada, O., Yata, K., Sakaguchi, H., Kurebayashi, J., Yawata, Y. and Ueki, A. (2000) "Expression and production of interleukin 10 in human myeloma cell lines", Br. J. Haematol. 111, 835-842.
37. Rozenfeld-Grano, G., Toren, A., Amariglio, N., Brok-Simoni, F. and Rechavi, G. (2001) "Mutation analysis of the FAS and TNFR apoptotic cascade genes in hematological malignancies", Exp. Hematol. 29, 228-233.
38. Kastrinakis, N.G., Gorgoulis, V.G., Foukas, P.G., Dimopoulos, M.A. and Kittas, C. (2001) "Molecular aspects of multiple myeloma", Ann. Oncol. 11, 1217-1228.
39. Landowski, T.H., Qu, N., Buyuksal, I., Painter, J.S. and Dalton, W.S. (1997) "Mutations in the Fas antigen in patients with multiple myeloma", Blood 90, 4266-4270.
40. Otsuki, T., Yata, K., Sakaguchi, H., Wada, H., Sugihara, T. and Ueki, A. (2002) "Cell biological roles of IL-10 in myeloma", J. Clin. Exp. Hematopathol. 42, 1-9.
41. Otsuki, T., Hata, H., Harada, N., Matsuzaki, H., Yata, K., Wada, H., Yawata, Y., Ueki, A. and Yamada, O. (2000) "Cellular biological differences between human myeloma cell lines KMS-12-PE and KMS-12-BM established from a single patient", Int. J. Hematol. 72, 216-222.
42. Otsuki, T., Yamada, O., Kurebayashi, J., Moriya, T., Sakaguchi, H., Kunisue, H., Yata, K., Uno, M., Yawat, Y. and Ueki, A. (2000) "Estrogen receptors in human myeloma cells", Cancer Res. 60, 1434-1441.
43. Tanaka, K., Otsuki, T., Sonoo, H., Yamamoto, Y., Udagawa, K., Kunisue, H., Arime, I., Yamamoto, S., Kurebayashi, J. and Shimozuma, K., "Semi-quantitative comparison of the differentiation markers and sodium iodide symporter messenger ribonucleic acids in papillary thyroid carcinomas using RT-PCR", Eur. J. Endocrinol. 142, 340-346.
44. Uno, M., Otsuki, T., Kurebayashi, J., Sakaguchi, H., Isozaki, Y., Ueki, A., Yata, K., Fujii, T., Hiratsuka, J., Akisada, T., Harada, T. and Imajo, Y. (2001) "Anti-HER2-antibody enhances irradiation-induced growth inhibition in head and neck carcinoma", Int. J. Cancer 94, 474-479.
45. 1", Br. J. Haematol. 114, 591-599.